Search

Your search keyword '"Campion, Loïc"' showing total 133 results
Start Over Author "Campion, Loïc" Search Limiters Academic (Peer-Reviewed) Journals
133 results on '"Campion, Loïc"'

1. PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial

Author

Dumont, Frédéric, Kepenekian, Vahan, Passot, Christophe, Ezanno-Manasterski, Anne-Cécile, Pocard, Marc, Raoul, Jean-Luc, Lelièvre, Bénédicte, Hiret, Sandrine, Senellart, Hélène, Pein, Francois, Raimbourg, Judith, Campion, Loic, Thibaudeau, Emilie, Paul, Julie, and Glehen, Olivier

Published
2024
Full Text
View/download PDF

4. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

Author

Féray, Cyrille, Campion, Loic, Mathurin, Philippe, Archambreaud, Isabelle, Mirabel, Xavier, Bronowicki, Jean Pierre, Rio, Emmanuel, Perret, Christophe, Mineur, Laurent, Oberti, Frédéric, Touchefeu, Yann, Gournay, Jérôme, Regnault, Hélène, Edeline, Julien, Rode, Agnès, Hillion, Patrick, Blanc, Jean Frédéric, Khac, Eric Nguyen, Azoulay, Daniel, Luciani, Alain, Preglisasco, Athena Galetto, Faurel-Paul, Elodie, Auble, Hélène, Mornex, Françoise, and Merle, Philippe

Published
2023
Full Text
View/download PDF

5. Pilot Feasibility Study: 18F-DPA-714 PET/CT Macrophage Imaging in Triple-Negative Breast Cancers (EITHICS).

Author

Rousseau, Caroline, Metz, Raphaël, Kerdraon, Olivier, Ouldamer, Lobna, Boiffard, Florence, Renaudeau, Karine, Ferrer, Ludovic, Vercouillie, Johnny, Doutriaux-Dumoulin, Isabelle, Mouton, Alexis, Le Thiec, Maelle, Morel, Agnès, Rusu, Daniela, Santiago-Ribeiro, Maria-Joao, Campion, Loïc, Arlicot, Nicolas, and Kraeber-Bodéré, Françoise

Published
2024
Full Text
View/download PDF

9. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

Author

Derrien, Jennifer, Guérin-Charbonnel, Catherine, Gaborit, Victor, Campion, Loïc, Devic, Magali, Douillard, Elise, Roi, Nathalie, Avet-Loiseau, Hervé, Decaux, Olivier, Facon, Thierry, Mallm, Jan-Philipp, Eils, Roland, Munshi, Nikhil C., Moreau, Philippe, Herrmann, Carl, Magrangeas, Florence, and Minvielle, Stéphane

Published
2021
Full Text
View/download PDF

10. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)

Author

Vaugier, Loig, Palpacuer, Clément, Rio, Emmanuel, Goineau, Aurore, Pasquier, David, Buthaud, Xavier, De Laroche, Guy, Beckendorf, Véronique, Sargos, Paul, Créhange, Gilles, Pommier, Pascal, Loos, Geneviève, Hasbini, Ali, Latorzeff, Igor, Silva, Marlon, Denis, Fabrice, Lagrange, Jean-Léon, Campion, Loic, and Supiot, Stéphane

Published
2019
Full Text
View/download PDF

13. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Author

Kraeber-Bodere, Françoise, Pallardy, Amandine, Maisonneuve, Hervé, Campion, Loïc, Moreau, Anne, Soubeyran, Isabelle, Le Gouill, Steven, Tournilhac, Olivier, Daguindau, Etienne, Jardel, Henry, Morineau, Nadine, Bouabdallah, Krimo, Gyan, Emmanuel, Moles, Marie-Pierre, Gressin, Remy, Berthou, Christian, Sadot, Sophie, Moreau, Philippe, Deau, Bénédicte, Bodet-Milin, Caroline, Cazeau, Anne-Laure, Garin, Etienne, Salaun, Pierre-Yves, Vuillez, Jean-Philippe, Gouilleux-Gruart, Valérie, Barbet, Jacques, Wegener, William A, Goldenberg, David M, Lamy, Thierry, and Soubeyran, Pierre

Published
2017
Full Text
View/download PDF

16. Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults

Author

Le Bourgeois, Amandine, Peterlin, Pierre, Guillaume, Thierry, Delaunay, Jacques, Duquesne, Alix, Le Gouill, Steven, Moreau, Philippe, Mohty, Mohamad, Campion, Loïc, and Chevallier, Patrice

Published
2016
Full Text
View/download PDF

20. Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS.

Author

Gluszak, Cassandre, Campion, Loïc, Seegers, Valérie, Cojocarasu, Oana, Commer, Jean-Marie, Priou, Frank, Rolland, Frédéric, Terret, Catherine, and Abadie-Lacourtoisie, Sophie

Subjects
*GERIATRIC assessment, *METASTASIS, *PROSTATE cancer, *OLDER patients, *MEDICAL screening
Abstract

Geriatric assessment (GA) can predict and improve treatment tolerance and estimate overall survival in older patients with cancer. Several international organizations promote GA; however, data related to its implementation in daily clinical practice are still limited. We aimed to describe GA implementation in patients over 75 years old with metastatic prostate cancer treated with docetaxel as first-line treatment, and with positive G8 screening test or frailty criteria. This retrospective real-world study included 224 patients treated from 2014 to 2021 in four French centers, including 131 patients with a theoretical indication of GA. Among the latter, 51 (38.9%) patients had GA. The main barriers to GA were the lack of systematic screening (32/80, 40.0%), unavailability of geriatric physician (20/80, 25.0%), and absence of referral despite a positive screening test (12/80, 15.0%). With GA performed in only one-third of the patients with a theoretical indication in daily clinical practice, mostly due to an absence of screening test, the use of GA is currently sub-optimal. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Prospective Multicentric Assessment of 68 Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.

Author

Lugat, Alexandre, Frampas, Éric, Touchefeu, Yann, Mirallié, Éric, Bras, Maëlle Le, Senellart, Hélène, Rauscher, Aurore, Fleury, Vincent, Campion, Loïc, Rohmer, Vincent, Couturier, Olivier-François, Lebtahi, Rachida, Rouzet, François, Ruszniewski, Philippe, Kraeber-Bodéré, Françoise, Bourgeois, Mickaël, and Ansquer, Catherine

Subjects
PANCREATIC tumors, RESEARCH, DISEASE progression, PERITONEAL cancer, POSITRON emission tomography computed tomography, RADIOISOTOPES, MAGNETIC resonance imaging, CANCER relapse, GASTROINTESTINAL tumors, GALLIUM isotopes, CANCER patients, NEUROENDOCRINE tumors, SINGLE-photon emission computed tomography, BONE metastasis, SOMATOSTATIN, DESCRIPTIVE statistics, RESEARCH funding, COMPUTED tomography, SENSITIVITY & specificity (Statistics), LONGITUDINAL method, NEUROTRANSMITTER receptors
Abstract

Simple Summary: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess 68Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, somatostatin receptor scintigraphy and MRI to evaluate whether this imaging modality results in therapeutic modifications. We confirm in a homogenous population of 105 grade 1 or 2 gastroenteropancreatic neuroendocrine tumors the higher sensitivity of 68Ga-DOTANOC PET/CT in per-patient and per-region analysis, as well as in the detection of primary tumor and small lesions such as peritoneal carcinomatosis and bone lesions leading to an impact on therapeutic management of almost half of the patients. The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma

Author

Salaun, Pierre-Yves, Campion, Loïc, Ansquer, Catherine, Frampas, Eric, Mathieu, Cédric, Robin, Philippe, Bournaud, Claire, Vuillez, Jean-Philippe, Taieb, David, Rousseau, Caroline, Drui, Delphine, Mirallié, Eric, Borson-Chazot, Françoise, Goldenberg, David M., Chatal, Jean-François, Barbet, Jacques, and Kraeber-Bodéré, Françoise

Published
2014
Full Text
View/download PDF

26. Real-World Data on Newly Diagnosed BRCA -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.

Author

Bini, Marta, Quesada, Stanislas, Meeus, Pierre, Rodrigues, Manuel, Leblanc, Eric, Floquet, Anne, Pautier, Patricia, Marchal, Frédéric, Provansal, Magali, Campion, Loïc, Causeret, Sylvain, Gourgou, Sophie, Ray-Coquard, Isabelle, Classe, Jean-Marc, Pomel, Christophe, De La Motte Rouge, Thibault, Barranger, Emmanuel, Savoye, Aude Marie, Guillemet, Cécile, and Gladieff, Laurence

Subjects
EPITHELIAL cell tumors, GENETIC mutation, OVARIAN tumors, CANCER chemotherapy, DESCRIPTIVE statistics, POLYMERASE chain reaction, BEVACIZUMAB, BREAST tumors
Abstract

Simple Summary: BRCA-mutated high-grade epithelial ovarian cancers represent a specific subset of gynecological malignancies. Real-world comprehensive data have been elusive to date. As such, we conducted a comprehensive description of clinicopathological and therapeutical characteristics via the Epidemiological Strategy and Medical Economics (ESME) data warehouse, which collects data from 18 French comprehensive cancer centers from the Unicancer network. This led to useful findings regarding the natural disease history of these patients in clinical practice, prior to the advent of poly-ADP ribose polymerase inhibitors. Background: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. Results: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. BRCA1 mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a BRCA2 mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, BRCA1- and BRCA2-mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (p-value = 0.053). Furthermore, five-year OS for BRCA1-mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for BRCA2-mutated ones (p-value = 0.029). Conclusions: This study reports the largest French multicenter cohort of BRCA-mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study

Author

Jézéquel, Pascal, Campion, Loïc, Spyratos, Frédérique, Loussouarn, Delphine, Campone, Mario, Guérin-Charbonnel, Catherine, Joalland, Marie-Pierre, André, Jean, Descotes, Françoise, Grenot, Catherine, Roy, Pascal, Carlioz, Antoine, Martin, Pierre-Marie, Chassevent, Agnès, Jourdan, Marie-Lise, and Ricolleau, Gabriel

Published
2012
Full Text
View/download PDF

41. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

Author

Oudoux, Aurore, Salaun, Pierre-Yves, Bournaud, Claire, Campion, Loïc, Ansquer, Catherine, Rousseau, Caroline, Bardet, Stéphane, Borson-Chazot, Françoise, Vuillez, Jean-Philippe, Murat, Arnaud, Mirallié, Eric, Barbet, Jacques, Goldenberg, David M., Chatal, Jean-François, and Kraeber-Bodéré, Françoise

Published
2007

42. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography

Author

Rousseau, Caroline, Devillers, Anne, Sagan, Christine, Ferrer, Ludovic, Bridji, Boumédiène, Campion, Loïc, Ricaud, Myriam, Bourbouloux, Emmanuelle, Doutriaux, Isabelle, Clouet, Martine, Berton-Rigaud, Dominique, Bouriel, Catherine, Delecroix, Valérie, Garin, Etienne, Rouquette, Sophie, Resche, Isabelle, Kerbrat, Pierre, Chatal, Jean François, and Campone, Mario

Published
2006
Full Text
View/download PDF

45. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

Author

Jézéquel Pascal, Campion Loïc, Charbonnel Catherine, Gouraud Wilfried, Gautier Fabien, Guillemin Yannis, Grau Morgan, Couriaud Cécile, Noël Bélinda, Campone Mario, Braun Frédérique, Barré Benjamin, Coqueret Olivier, Barillé-Nion Sophie, and Juin Philippe

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Anti-apoptotic signals induced downstream of HER2 are known to contribute to the resistance to current treatments of breast cancer cells that overexpress this member of the EGFR family. Whether or not some of these signals are also involved in tumor maintenance by counteracting constitutive death signals is much less understood. To address this, we investigated what role anti- and pro-apoptotic Bcl-2 family members, key regulators of cancer cell survival, might play in the viability of HER2 overexpressing breast cancer cells. Methods We used cell lines as an in vitro model of HER2-overexpressing cells in order to evaluate how anti-apoptotic Bcl-2, Bcl-xL and Mcl-1, and pro-apoptotic Puma and Bim impact on their survival, and to investigate how the constitutive expression of these proteins is regulated. Expression of the proteins of interest was confirmed using lysates from HER2-overexpressing tumors and through analysis of publicly available RNA expression data. Results We show that the depletion of Mcl-1 is sufficient to induce apoptosis in HER2-overexpressing breast cancer cells. This Mcl-1 dependence is due to Bim expression and it directly results from oncogenic signaling, as depletion of the oncoprotein c-Myc, which occupies regions of the Bim promoter as evaluated in ChIP assays, decreases Bim levels and mitigates Mcl-1 dependence. Consistently, a reduction of c-Myc expression by inhibition of mTORC1 activity abrogates occupancy of the Bim promoter by c-Myc, decreases Bim expression and promotes tolerance to Mcl-1 depletion. Western blot analysis confirms that naïve HER2-overexpressing tumors constitutively express detectable levels of Mcl-1 and Bim, while expression data hint on enrichment for Mcl-1 transcripts in these tumors. Conclusions This work establishes that, in HER2-overexpressing tumors, it is necessary, and maybe sufficient, to therapeutically impact on the Mcl-1/Bim balance for efficient induction of cancer cell death.

Published
2011
Full Text
View/download PDF

46. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

Author

Calais Gilles, Burtin Pascal, Carrie Christian, Salemkour Augustin, Vendrely Véronique, Chevelle Christian, Vié Brigitte, Martin Laurent, Leduc Bernard, Cellier Patrice, Campion Loïc, Boisdron-Celle Michèle, Morel Alain, Berger Virginie, and Gamelin Erick

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Considerable variation in intravenous 5-fluorouracil (5-FU) metabolism can occur due to the wide range of dihydropyrimidine dehydrogenase (DPD) enzyme activity, which can affect both tolerability and efficacy. The oral fluoropyrimidine tegafur-uracil (UFT) is an effective, well-tolerated and convenient alternative to intravenous 5-FU. We undertook this study in patients with locally advanced rectal cancer to evaluate the efficacy and tolerability of UFT with leucovorin (LV) and preoperative radiotherapy and to evaluate the utility and limitations of multicenter staging using pre- and post-chemoradiotherapy ultrasound. We also performed a validated pretherapy assessment of DPD activity and assessed its potential influence on the tolerability of UFT treatment. Methods This phase II study assessed preoperative UFT with LV and radiotherapy in 85 patients with locally advanced T3 rectal cancer. Patients with potentially resectable tumors received UFT (300 mg/m/2/day), LV (75 mg/day), and pelvic radiotherapy (1.8 Gy/day, 45 Gy total) 5 days/week for 5 weeks then surgery 4-6 weeks later. The primary endpoints included tumor downstaging and the pathologic complete response (pCR) rate. Results Most adverse events were mild to moderate in nature. Preoperative grade 3/4 adverse events included diarrhea (n = 18, 21%) and nausea/vomiting (n = 5, 6%). Two patients heterozygous for dihydropyrimidine dehydrogenase gene (DPYD) experienced early grade 4 neutropenia (variant IVS14+1G > A) and diarrhea (variant 2846A > T). Pretreatment ultrasound TNM staging was compared with postchemoradiotherapy pathology TN staging and a significant shift towards earlier TNM stages was observed (p < 0.001). The overall downstaging rate was 42% for primary tumors and 44% for lymph nodes. The pCR rate was 8%. The sensitivity and specificity of ultrasound for staging was poor. Anal sphincter function was preserved in 55 patients (65%). Overall and recurrence-free survival at 3 years was 86.1% and 66.7%, respectively. Adjuvant chemotherapy was administered to 36 node-positive patients (mean duration 118 days). Conclusion Preoperative chemoradiotherapy using UFT with LV plus radiotherapy was well tolerated and effective and represents a convenient alternative to 5-FU-based chemoradiotherapy for the treatment of resectable rectal cancer. Pretreatment detection of DPD deficiency should be performed to avoid severe adverse events.

Published
2011
Full Text
View/download PDF

49. 68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes.

Author

Barbaud, Matthieu, Frindel, Mathieu, Ferrer, Ludovic, Le Thiec, Maelle, Rusu, Daniela, Rauscher, Aurore, Maucherat, Bruno, Baumgartner, Pierre, Fleury, Vincent, Colombié, Mathilde, Thierry‐Morel, Agnes, Kraeber‐Bodéré, Françoise, Campion, Loïc, and Rousseau, Caroline

Published
2019
Full Text
View/download PDF

50. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Author

Bennouna, Jaafar, André, Thierry, Campion, Loïc, Hiret, Sandrine, Miglianico, Laurent, Mineur, Laurent, Touchefeu, Yann, Artru, Pascal, Asmis, Timothy, Bouché, Olivier, Borde, Florence, Kavan, Petr, You-Heng Lam, Rajpar, Laetitia-Shana, Emile, Jean-François, Jouffroy, Claire, Gill, Sharlene, Taïeb, Julien, and Lam, You-Heng

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results